GlassScriptPhysician profile
Keenan Smart
NPI 1790120483
$5,526.86
in general payments reported to CMS, 2019-2025
31 companies · $1,397 in 2025
The $1,397 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $200 · 2021: $719 · 2022: $770 · 2023: $947 · 2024: $1,151 · 2025: $1,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,445 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,445.26 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,349.68 | 2021-2025 | Caplyta |
| Abbvie INC. | $594.74 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $501.85 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $415.77 | 2019-2025 | Spravato, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $350.11 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $336.55 | 2021-2025 | Azstarys |
| Tris Pharma INC | $220.42 | 2020-2025 | Dyanavel Xr, Onyda Xr |
| Sunovion Pharmaceuticals INC. | $215.75 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.36 | 2020-2023 | Trintellix |
| Alkermes, INC. | $161.13 | 2021-2024 | Lybalvi, Aristada |
| Ironshore Pharmaceuticals INC. | $160.52 | 2019-2024 | Jornay Pm |
| Adlon Therapeutics L.P. | $156.95 | 2020-2021 | |
| Axsome Therapeutics, INC. | $135.31 | 2022-2025 | Auvelity |
| Brainsway USA INC | $123.55 | 2023 | |
| Noven Therapeutics, LLC | $85.77 | 2023-2025 | Xelstrym, Secuado |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $85.13 | 2025 | Jornay Pm |
| Lundbeck LLC | $59.49 | 2019-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $56.25 | 2023-2025 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.90 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $45.32 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $37.94 | 2024 | Fanapt |
| Shire North American Group INC | $37.92 | 2019 | |
| Idorsia Pharmaceuticals US INC | $32.27 | 2022-2023 | Quviviq |
| Allergan, INC. | $23.14 | 2019 | |
| Owp Pharmaceuticals, INC. | $20.78 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $20.75 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $19.47 | 2019 | |
| Novo Nordisk INC | $16.86 | 2021 | |
| Vertical Pharmaceuticals, LLC | $16.25 | 2025 | Relexxii |
| Indivior INC. | $13.52 | 2022 | |
| Neuronetics, INC. | $10.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keenan Smart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.